Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew McGarry

Showing results (21-30 of 32) with videos related to

Pageof 4
Sort By:
Journal of Huntington'S Disease|June 9, 2020
Additional Safety and Exploratory Efficacy Data at 48 and 60 Months from Open-HART, an Open-Label Extension Study of Pridopidine in Huntington DiseaseAndrew McGarry, Peggy Auinger, Karl Kieburtz, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|October 27, 2023
A Randomized Phase 3 Study Comparing P2B001 to its Components (Low-Dose Extended-Release Rasagiline and Pramipexole) and to Optimized Doses of Marketed Extended-Release Pramipexole in Early Parkinson's DiseaseC Warren Olanow, Robert A Hauser, Daniel J Burdick, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|May 3, 2024
Continuous Levodopa Delivery with an Intraoral Micropump System: An Open-Label Pharmacokinetics and Clinical StudyC Warren Olanow, Deborah McIntyre, Michele Matarazzo, et al.
Journal of Parkinson'S Disease|January 22, 2024
A Phase I, Randomized, SAD, MAD, and PK Study of Risvodetinib in Older Adults and Parkinson's DiseaseMilton H Werner, C Warren Olanow, Andrew McGarry, et al.
The Lancet. Neurology|December 20, 2018
Safety and efficacy of pridopidine in patients with Huntington's disease (PRIDE-HD): a phase 2, randomised, placebo-controlled, multicentre, dose-ranging studyRalf Reilmann, Andrew McGarry, Igor D Grachev, et al.
Mayo Clinic Proceedings. Digital Health|June 12, 2025
Much More Than the Malady: The Promise of a Web-Based Digital Platform Incorporating Self-Report for Research and Clinical Care in Mild Cognitive ImpairmentAndrew McGarry, Oliver Roesler, Jackson Liscombe, et al.
Brain Sciences|January 8, 2025
Galantamine-Memantine Combination in the Treatment of Parkinson's Disease DementiaEmma D Frost, Swanny X Shi, Vishnu V Byroju, et al.
The Lancet. Neurology|December 15, 2023
Safety, tolerability, and efficacy of NLY01 in early untreated Parkinson's disease: a randomised, double-blind, placebo-controlled trialAndrew McGarry, Shane Rosanbalm, Mika Leinonen, et al.
Muscle & Nerve|May 27, 2025
Operational Development and Launch of an Adaptive Platform Trial in Amyotrophic Lateral Sclerosis: Processes and Learnings From the First Four Regimens of the HEALEY ALS Platform TrialBrittney A Harkey, Sofia Distefano, Jaclyn A Pagliaro, et al.
Neurology|December 4, 2016
A randomized, double-blind, placebo-controlled trial of coenzyme Q10 in Huntington diseaseAndrew McGarry, Michael McDermott, Karl Kieburtz, et al.
Pageof 4

Showing results (21-30 of 32) with videos related to

Sort By:
Pageof 4
Journal of Huntington'S Disease|June 9, 2020
Additional Safety and Exploratory Efficacy Data at 48 and 60 Months from Open-HART, an Open-Label Extension Study of Pridopidine in Huntington DiseaseAndrew McGarry, Peggy Auinger, Karl Kieburtz, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|October 27, 2023
A Randomized Phase 3 Study Comparing P2B001 to its Components (Low-Dose Extended-Release Rasagiline and Pramipexole) and to Optimized Doses of Marketed Extended-Release Pramipexole in Early Parkinson's DiseaseC Warren Olanow, Robert A Hauser, Daniel J Burdick, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|May 3, 2024
Continuous Levodopa Delivery with an Intraoral Micropump System: An Open-Label Pharmacokinetics and Clinical StudyC Warren Olanow, Deborah McIntyre, Michele Matarazzo, et al.
Journal of Parkinson'S Disease|January 22, 2024
A Phase I, Randomized, SAD, MAD, and PK Study of Risvodetinib in Older Adults and Parkinson's DiseaseMilton H Werner, C Warren Olanow, Andrew McGarry, et al.
The Lancet. Neurology|December 20, 2018
Safety and efficacy of pridopidine in patients with Huntington's disease (PRIDE-HD): a phase 2, randomised, placebo-controlled, multicentre, dose-ranging studyRalf Reilmann, Andrew McGarry, Igor D Grachev, et al.
Mayo Clinic Proceedings. Digital Health|June 12, 2025
Much More Than the Malady: The Promise of a Web-Based Digital Platform Incorporating Self-Report for Research and Clinical Care in Mild Cognitive ImpairmentAndrew McGarry, Oliver Roesler, Jackson Liscombe, et al.
Brain Sciences|January 8, 2025
Galantamine-Memantine Combination in the Treatment of Parkinson's Disease DementiaEmma D Frost, Swanny X Shi, Vishnu V Byroju, et al.
The Lancet. Neurology|December 15, 2023
Safety, tolerability, and efficacy of NLY01 in early untreated Parkinson's disease: a randomised, double-blind, placebo-controlled trialAndrew McGarry, Shane Rosanbalm, Mika Leinonen, et al.
Muscle & Nerve|May 27, 2025
Operational Development and Launch of an Adaptive Platform Trial in Amyotrophic Lateral Sclerosis: Processes and Learnings From the First Four Regimens of the HEALEY ALS Platform TrialBrittney A Harkey, Sofia Distefano, Jaclyn A Pagliaro, et al.
Neurology|December 4, 2016
A randomized, double-blind, placebo-controlled trial of coenzyme Q10 in Huntington diseaseAndrew McGarry, Michael McDermott, Karl Kieburtz, et al.
Pageof 4